KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Operating Income: 2010-2025

Historic Operating Income for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$178.0 million.

  • Novavax's Operating Income fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • Latest data reveals that Novavax reported Operating Income of -$178.0 million as of Q3 2025, which was down 276.13% from $101.1 million recorded in Q2 2025.
  • Novavax's 5-year Operating Income high stood at $515.5 million for Q1 2025, and its period low was -$825.0 million during Q4 2021.
  • Its 3-year average for Operating Income is -$34.3 million, with a median of -$131.1 million in 2024.
  • In the last 5 years, Novavax's Operating Income slumped by 1,931.06% in 2021 and then surged by 455.94% in 2025.
  • Quarterly analysis of 5 years shows Novavax's Operating Income stood at -$825.0 million in 2021, then skyrocketed by 70.44% to -$243.9 million in 2022, then increased by 24.73% to -$183.6 million in 2023, then climbed by 28.59% to -$131.1 million in 2024, then crashed by 32.83% to -$178.0 million in 2025.
  • Its Operating Income was -$178.0 million in Q3 2025, compared to $101.1 million in Q2 2025 and $515.5 million in Q1 2025.